secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001493152-23-043142
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell reports new Phase 2 responder with 3-cycle orbital tumor resolution after 7 prior failed regimens
--------------------------------------------------------------------------------

- Patient with proptosis from orbital metastatic breast cancer had remarkable improvement and pain reduction after 3 cycles of Bria-IMT combo.
- Heavily pretreated patient had failed 7 prior regimens; continues treatment with well-tolerated regimen.
- Second reported case of orbital tumor resolution; first patient had failed 12 regimens and 16 agents.
- Additional Phase 2 survival updates and clinical data to be presented at San Antonio Breast Cancer Symposium Dec 6-7, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/0001493152-23-043142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer